ABSTRACT Monoclonal antibodies with selectivity for human lung cancer were produced by immunizing BALB/c mice with an established line of human small cell lung cancer (NCI-H69) and fusing the mouse spleen cells to mouse myeloma line X63-Ag8.653. The resulting hybrid cells were initially screened' by immunoautoradiography for production of antibodies that would react with NCI-H69 and another small cell lung cancer line (NCI-H128) but not its autologous B-lymphoblastoid line (NCI-H128BL). Stable monoclonal antibody-producing lines were isolated by repeated cloning. Three independently derived monoclonal antibodies, designated 525A5, 534F8, and 538F12, were found to react with three of the major types of human lung cancer (small cell, adenocarcinoma, and squamous carcinoma). They did not react with bronchioloalveolar and large cell lung cancers, myeloma, lymphomas, leukemias, osteogeneic sarcoma, mesothelioma, hypernephroma, malignant melanoma, simian virus 40-transformed human fetal lung cells, skin fibroblast lines, human B-lymphoblastoid lines, human erythrocytes, and rodent cells. Interestingly, these antibodies also bound to three out ofthree human neuroblastomas and two out of three breast cancers but failed to react with mouse neuroblastoma and rat pheochromocytoma. The monoclonal antibodies reacted with human small cell lung cancer tumors obtained at autopsy, but had insignificant reactions with normal human lung, liver, spleen, and skeletal muscle. We conclude that monoclonal antibodies have been generated that react with common antigenic determinants expressed on several human lung cancer types, neuroblastoma, and some breast cancers, but are not detectable by our current assays on a variety of other human tumors or normal adult human tissues. Such antibodies are of potential clinical and biological importance.
Antibodies with sufficient specificity for human lung cancer are potentially important diagnostic and therapeutic tools. Several groups have prepared polyclonal antibodies with potential specificity for lung cancer by using standard immunologic methods (1) (2) (3) (4) (5) (6) (7) (8) . The development of somatic cell hybrid technology for the production of monoclonal antibodies (9) offers a different approach, and several monoclonal antibodies have been reported with various degrees of specificity to a variety of human neoplasms (10) (11) (12) (13) (14) (15) (16) (17) . In this report, we describe the use of this technology to prepare antibodies with specificity for human lung cancer. As a first approach, we wanted to make monoclonal antibodies that react selectively with lung tumors but not with autologous histocompatibility antigens. Thus, we immunized mice with a line of small cell lung cancer (SCLC) and screened the resultant hybrid cell antibodies for reactivity against the immunizing line and another SCLC line and for lack ofreactivity with an autologous B-lymphoblastoid cell line. Using this strategy, we have isolated, cloned, and developed stable hybrid cell lines producing antibodies that detect determinants expressed on human SCLC, and to a lesser extent on adenocarcinomas and squamous cell carcinomas of the lung, but not on a variety of normal tissue or human cell lines. Interestingly, these determinants are also found on human neuroblastoma and breast cancer cell lines.
MATERIALS AND METHODS Cells. The sources or references for the various cell lines used are shown in Table 1 , and they were grown as previously reported (18) in RPMI 1640 medium or Dulbecco's modified Ea- gle's medium supplemented with 10% heat-inactivated fetal calf serum (all reagents from GIBCO). All human lines exhibited human enzymes by starch gel electrophoresis (21) . All human tumor cell lines, established in our laboratory, were from patients with documented histology of the stated tumor type, and all induced nude mouse heterotransplants with a histology similar to that seen in the patients' tumors. In addition, SCLC cell lines had typical SCLC cytology, suspension culture appearance, and high levels of L-dopa decarboxylase (EC 4.1.1.28) (18) . Human SCLC cultures that transformed to large cell cytology came from a patient whose tumor had mixtures of SCLC and large cell histology (line NCI-H82) or occurred spontaneously during long-term tissue culture (line NCI-N231/417). These transformants had reduced levels of L-dopa decarboxylase or no enzyme at all (22) . The B-lymphoblastoid lines were prepared and characterized as described (23) (27) , using a mouse spleen cell feeder layer. This Abbreviations: SCLC, human small cell lung cancer; PINaCl, phosphate-buffered saline; GAM, affinity-purified goat antibodies to mouse immunoglobulin Fab fragment; SAM, affinity-purified sheep antibodies to mouse immunoglobulin Fab fragment. * To whom reprint requests should be addressed. 4591
The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Immunoassays. Affinity-purified sheep anti-mouse immunoglobulin (SAM; Cappel Laboratories, Cochranville, PA) and goat antirmouse immunoglobulin (GAM; T. Chused, National Cancer Institute), both ofwhich are directed against the mouse immunoglobulin Fab region, and purified staphylococcal protein A (Pharmacia) were labeled with '"I (Amersham) by the chloramine-T method (29) to specific activities of 14, 16, and 27 uCi/4gofprotein, respectively (1 Ci = 3.7 x 1010 becquerels). (30) to detect binding of the mouse monoclonal antibodies. The cloned stabilized lines were injected into pristane-primed mice, and the resultant ascitic fluids had titers over 1000-fold greater than those of culture fluid supernatants and were used for characterization. Fig. 1 (Table 2) . Interestingly, these antibodies also bound to three out of three human neuroblastoma and two out of three breast cancer cell lines but failed to react with rodent neuroblastoma, pheochromocytoma, or insulinoma cells (Table 3) . When tients without malignant disease, and the samples were tested for their ability to bind the monoclonal antibodies (Table 4 ). The monoclonal antibodies bound to cells from four separate tumors obtained from the lung and metastatic sites, but failed to give significant reactions with uninvolved lung, liver, skeletal muscle, kidney, or spleen cell preparations.
DISCUSSION
By screening for hybrid cell-produced antibodies that react with two SCLC lines but not with an autologous B-lymphoblastoid cell line we have produced monoclonal antibodies that react with all SCLC tumors tested, some other types of human lung cancer, human neuroblastomas, and breast cancer cell lines, but not with a variety ofhuman malignant and nonmalignant tissues and lines or rodent lines. Of interest, the antibodies react with lung cancer cells that had converted from small cell to large cell histology but not with tumors apparently derived from pure large cell lung carcinomas. The monoclonal antibodies gave significant reactions with SCLC tumors taken directly from patients without intervening culture, whereas they failed to react with several types of adult normal tissue. Thus, the antigens detected are not dependent on growth in tissue culture for their expression as demonstrated for fetal antigens on human skin fibroblasts (46) . However, our studies do not exclude the possibility that the antigens detected may be present on a subpopulation of normal cells such as the Kultschitzky cells, from which SCLC are believed to be derived (22, 47) . Thus, the SCLC antigens detected by our monoclonal antibodies may be a clonal expansion ofnormally expressed antigens ofeither adult or fetal nature, as seen for some other tumors (6, 14, 48) .
The monoclonal antibodies detect determinants present on the SCLC tumors and neuroblastomas so far tested, and to a lesser extent, on some non-small cell lung tumors dodermal structures (as do other bronchogenic carcinomas) (22, 47, 49) . Absorbed heteroantisera have been prepared against human lung cancers or other tumors that detect antigens that are: (i) shared between SCLC and endodermal structures but not with neural crest tissues, (ii) shared between SCLC and neural crest derived tumors but not with endodermal tissues, or (iii) apparently restricted to SCLC . Surprisingly, our monoclonal antibodies appear to detect antigenic determinants that are preferentially expressed on SCLC, though also present on some endodermal tumors (e.g., adenocarcinoma ofthe lung) and ectodermal tumors (breast cancer) and some but not all neural crest-derived neoplasms (e.g., neuroblastomas but not melanomas). These monoclonal antibodies demonstrate an unexpected antigenic relationship between neural crest and endodermal tumors. Thus, they should aid in the study ofthe embryologic origin and interrelationship of lung cancer and other human tumors. In addition, the monoclonal antibodies we have produced appear to have sufficient specificity to be ofpotential clinical, diagnostic, and therapeutic use.
Note Added in Proof. Purified, directly l"sI-labeled, monoclonal antibodies 534F8 and 538F12 give a significant binding reaction with kidney but not with lung, liver, brain, muscle, gall bladder, urinary bladder, or spleen. Tissues were obtained at autopsy (courtesy of L. Ortega, Washington Veterans Administration Medical Center Laboratory Service), minced with fine scissors, passed through a 300-,m grid mesh screen, taken up in PJNaCl, and dispersed through a 25-gauge needle. The cell suspension was washed three times in PJNaCl, fixed with 0.25% glutaraldehyde/P]NaCl for 5 min, washed twice again, and then adjusted to a 1% vol/vol suspension, and 0.05 ml of this suspension was added to each well of a polyvinyl microtiter plate and fixed as for the cell lines.
'"I-GAM and`mI-SAM were used to test the binding of monoclonal antibodies to autopsy specimens because of the large background binding of '25I-protein A to these human tissue samples. Results in cpm are the average of quadruplicate determinations with the backgrounds (200-400 cpm) subtracted. * AF, ascites fluids; TCS, tissue culture supernatant fluids.
